Loading
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Latest filing published 08 Sept 2026 for HLS Therapeutics Inc., €4,779.
Insider track record
Disclosed buys
2
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Ryan Christopher Lennox: trading record in brief
This profile gathers the share dealings of Ryan Christopher Lennox in HLS Therapeutics Inc. In total, 5 filings cover trades dated from 7 May 2018 to 8 September 2026.
The open-market record is one-sided, with 2 purchases worth €9,372 and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant. 2026 to date brings 1 purchase and no sales.
The record was last updated on 8 September 2026 with an open-market purchase (€4,779) in HLS Therapeutics Inc. Between a trade and the moment it shows up on SEDI, the median delay is 4 days. The shorter that gap, the sooner other investors can see what insiders have done. Source: insider filings from SEDI. Past trades are no guide to future returns.
Companies and markets linked to Ryan Christopher Lennox
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
2,000 shares@ CA$3.83Common SharesTSXSEDI:4774987
35,000 shares@ CA$4.140.12% mcap100.0% of flowRestricted Share UnitsTSXSEDI:4741930
Restricted Share UnitsTSXSEDI:4741929
3 of 3 declarations
